Tower Research Capital (TRC)’s FibroBiologics FBLG Stock Holding History

Tower Research Capital (TRC)’s Portfolio FBLG Stock Details FBLG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.48K	Buy	4,728 +4,268	+928%	+$4.96K	﹤0.01%	4382
2026 Q1	$607	Sell	460 -445	-49%	-$2.65K	﹤0.01%	4829
2025 Q4	$4.07K	Buy	905 +57	+7%	+$402	﹤0.01%	4264
2025 Q3	$9.27K	Buy	848 +87	+11%	+$1.04K	﹤0.01%	4031
2025 Q2	$9.47K	Buy	761 +282	+59%	+$5.09K	﹤0.01%	3990
2025 Q1	$8.63K	Buy	479 +248	+107%	+$7.08K	﹤0.01%	3873
2024 Q4	$9.25K	Buy	231 +23	+11%	+$1.23K	﹤0.01%	3920
2024 Q3	$12.8K	Buy	+208	New	+$13.8K	﹤0.01%	3556

Other funds holding FBLG

CFP

Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return

FEG

Fund Evaluation Group Cincinnati, Ohio $3.7B AUM 16.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Tower Research Capital (TRC)'s FBLG Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its FibroBiologics (FBLG) stake by 928% in Q2 2026, buying an estimated $4.96K and bringing the position to 4,728 shares worth $4.48K. The position accounts for ﹤0.01% of the portfolio, ranked #4382.

Tower Research Capital (TRC) first reported a position in FBLG in Q3 2024 and has held it in 8 quarters since. The position peaked at $12.8K in Q3 2024. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

Tower Research Capital (TRC) held 4,728 shares of FibroBiologics worth $4.48K as of Q2 2026.
Tower Research Capital (TRC) bought 4,268 FibroBiologics shares in Q2 2026, an estimated $4.96K.
FibroBiologics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4382 holding.
Tower Research Capital (TRC) first reported a position in FibroBiologics in Q3 2024 and has held it in 8 quarters since.
Tower Research Capital (TRC)'s FibroBiologics position peaked at $12.8K in Q3 2024.
16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.